secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silence Therapeutics plc (SLN)
CIK:        0001479615
Form:       8-K
Filed at:   2025-12-15T23:59:59+00:00
Accession:  0001193125-25-319156
Event type: leadership
Sentiment:  negative
Materiality: 0.65
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silence Therapeutics CEO Craig Tooman departs by mutual consent; Chairman Iain Ross named interim CEO
--------------------------------------------------------------------------------

- Craig Tooman stepped down as President, CEO and Board member effective Dec 14, 2025 by mutual consent.
- Chairman Iain Ross appointed as interim principal executive officer effective immediately.
- James Ede-Golightly re-appointed to Board; previously served as Non-Executive Director from 2019 to June 2025.
- Company expects to add a US-based Board member in due course.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525319156/0001193125-25-319156-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1479615/000119312525319156/sln-20251214.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-319156

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer